Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound Paclitaxel + Carboplatin vs Epirubicin + Docetaxel in Neoadjuvant TNBC
NCT04136782Phase 4Recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Jul 2021
- Primary completion
- Nov 2025
- Modality
- Polymer-based Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 4 trial of nab-paclitaxel, carboplatin in triple-negative breast cancer (TNBC), sponsored by Shengjing Hospital of China Medical University. Started Jul 2021; status: recruiting.
02
Drugs
nab-paclitaxelcarboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04136782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04136782.